/PRNewswire/ The National Cancer Institute (NCI), part of the National Institutes of Health, under formal collaboration with Promontory Therapeutics Inc., a.
By Daniella Parra Promontory Therapeutics, a clinical stage pharmaceutical company focused on oncology, said it treated its first four patients in France for late-stage metastatic castration-resistant prostate cancer (mCRPC). The study is being led by oncologist Dr. Karim Fizazi at Gustave Roussy and the Military Hospital (HIA) Bégin in Paris, the company said. The trial […]
Promontory Therapeutics Inc : Promontory Therapeutics Expands Phase 2 Trial of PT-112 in Metastatic Castrate-Resistant Prostate Cancer to France finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, will participate in.